G101SPM Posted - 1 hour ago

@S_Franconi per request: $EWTX $19.74 up two plus from last readout--- carries SPM 84.56 tag to $26.00

S_Franconi Posted - 4 hours ago

$EWTX From what I understand gene therapy can essentially change a Duchene's patient into a Becker's patient and EWTX has the medicine to prevent severe muscle damage in Becker's patients.

buckeyejoe88 Posted - 4 hours ago

@dixiebull could I get your thoughts on $EWTX ?

RamenLives Posted - 5 hours ago

$EWTX

buckeyejoe88 Posted - 5 hours ago

$EWTX excellent 5 day run. Earnings coming up

S_Franconi Posted - 1 day ago

$EWTX This is interesting.

S_Franconi Posted - 1 day ago

$EWTX Very nice day here!

greenype Posted - 2 days ago

$EWTX

RamenLives Posted - 04/30/24

$EWTX My mouth is watering just thinking if we could a $40 BO...

S_Franconi Posted - 04/30/24

$EWTX On my buyout/gainer list.

greenype Posted - 04/30/24

$EWTX probably nothing

markovb343 Posted - 04/29/24

$EWTX nice bounce off 15, any idea what's going on?

greenype Posted - 04/29/24

$EWTX

Youngandhappy Posted - 04/25/24

$EWTX $META oooooooooooooof!

Youngandhappy Posted - 04/23/24

$EWTX https://www.biospace.com/article/releases/edgewise-receives-european-medicines-agency-ema-orphan-drug-designations-for-sevasemten-edg-5506-for-the-treatment-of-becker-and-duchenne-muscular-dystrophies/

RamenLives Posted - 04/23/24

$EWTX Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU MT NEWSWIRES 9:34 AM ET 04/23/2024 09:34 AM EDT, 04/23/2024 (MT Newswires) -- Edgewise Therapeutics (EWTX) said Tuesday that the European Medicines Agency granted orphan drug designations for its for sevasemten product candidate for the treatment of Becker muscular dystrophy and Duchenne muscular dystrophy. The designation is granted to drugs and biologics intended for the treatment, diagnosis, or prevention of rare diseases or conditions that affect no more than five in 10,000 people in the European Union, said the company. The designation comes with certain benefits such as lower regulatory fees, centralized authorization procedures, and up to 10 years of market exclusivity, the company added. Edgewise Therapeutics (EWTX) said sevasemten is currently in late-stage clinical trials for Becker muscular dystrophy and is also being studied in Duchenne. The drug also has orphan drug designation in the US.

briefingcom Posted - 04/23/24

$EWTX: Edgewise Therapeutics announces that the European Medicines Agency has granted Orphan Drug Designations for sevasemten for the treatment of Becker muscular dystrophy and for the treatment of Duchenne muscular dystrophy https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240423080802EWTX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

DonCorleone77 Posted - 04/23/24

$EWTX EMA grants Orphan Drug Designations for Edgewise's sevasemten to treat Becker Edgewise Therapeutics announced that the European Medicines Agency EMA has granted Orphan Drug Designations for sevasemten for the treatment of Becker muscular dystrophy and for the treatment of Duchenne muscular dystrophy Duchenne . Sevasemten is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage. Sevasemten is currently in late-stage clinical trials for individuals with Becker and is also being studied in Duchenne. "Receiving Orphan Drug designation in the U.S. and now in Europe highlights alignment across regions on the urgent and critical need for new and better therapeutic options for people living with Becker or Duchenne," said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. "We are focused on advancing these muscle-targeted therapeutics as quickly as possible through clinical development for these communities."

Stock_Titan Posted - 04/23/24

$EWTX Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies https://www.stocktitan.net/news/EWTX/edgewise-receives-european-medicines-agency-ema-orphan-drug-ciotys0046mw.html

Youngandhappy Posted - 04/21/24

$EWTX $ICU Edgewise: Important future MD cure, good results thus far. MB

S_Franconi Posted - 04/19/24

$EWTX 2-Year Topline Results from the ARCH Study of Sevasemten in Adults with Becker Muscular Dystrophy https://s29.q4cdn.com/148823924/files/doc_presentations/2024/04/arch-slides_investor-call_vfinal-for-website.pdf

S_Franconi Posted - 04/16/24

$EWTX & it begins.

lob11 Posted - 04/15/24

$EWTX Seems Mr market is yawning

Stock_Titan Posted - 04/15/24

$EWTX Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) https://www.stocktitan.net/news/EWTX/edgewise-therapeutics-announces-positive-two-year-topline-results-6vo5kxodx7nk.html

R_NW Posted - 04/13/24

$EWTX added a position in the last week.

Youngandhappy Posted - 04/11/24

$EWTX $ICU MB

TICKERTUTOR Posted - 04/11/24

$EWTX mentioned on CNBC

RamenLives Posted - 04/04/24

$EWTX what happened here?

Youngandhappy Posted - 04/04/24

$EWTX Glad I sold a hundred yesterday. Sheesh.

S_Franconi Posted - 04/04/24

$EWTX Watchers 281.